R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

NCT ID: NCT00773955

Last Updated: 2014-05-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-11-30
• Study Completion Date: 2010-08-31

Brief Summary

This phase II trial is studying how well R-(-)-gossypol acetic acid works in treating patients with recurrent extensive-stage small cell lung cancer. Drugs used in chemotherapy, such as R-(-)-gossypol acetic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Detailed Description

PRIMARY OBJECTIVES:

I. To determine the objective response rate of R-(-)-gossypol in patients with recurrent chemotherapy-sensitive extensive stage small cell lung cancer.

II. To determine the time to disease progression. III. To determine the overall survival. IV. To assess the toxicities associated with this drug. V. To explore whether intratumoral Bcl-2 family member expression correlates with sensitivity to targeting by R-(-)-gossypol.

VI. To explore whether the administration of R-(-)-gossypol causes specific induction of the intrinsic apoptotic pathway.

OUTLINE: This is a multicenter study.

Patients receive oral R-(-)-gossypol once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Blood is collected periodically during treatment for pharmacodynamic analysis. Peripheral blood mononuclear cells are analyzed via protein isolation and western blotting for Bcl-2, cytoplasmic release of cytochrome c, and caspase activation. Available tumor tissue blocks are assessed by immunohistochemistry.

After completion of study therapy, patients are followed periodically for up to 5 years.

Conditions

Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment (R-(-)-gossypol)

Patients receive oral R-(-)-gossypol once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Group Type: EXPERIMENTAL

R-(-)-gossypol acetic acid

Intervention Type: DRUG

Given orally

pharmacological study

Intervention Type: OTHER

Correlative studies

laboratory biomarker analysis

Intervention Type: OTHER

Correlative studies

Interventions

R-(-)-gossypol acetic acid

Given orally

Intervention Type: DRUG

pharmacological study

Correlative studies

Intervention Type: OTHER

laboratory biomarker analysis

Correlative studies

Intervention Type: OTHER

Other Intervention Names

AT-101; pharmacological studies

Eligibility Criteria

Inclusion Criteria

• Histologically or cytologically confirmed small cell lung cancer

• Extensive stage disease
• Recurrent disease
• Measurable disease
• Chemotherapy-sensitive disease, defined as:

• No progression during first-line chemotherapy
• No disease recurrence < 2 months after completion of first-line chemotherapy
• Must have received prior platinum-based chemotherapy
• No symptomatic or progressive brain metastases

• Patients with previously treated brain metastases who are clinically and radiographically stable or improved and have been off steroids ≥ 14 days are eligible
• ECOG performance status 0-2
• Life expectancy > 12 weeks
• Leukocytes ≥ 3,000/μL
• ANC ≥ 1,500/μL
• Platelet count ≥ 100,000/μL
• Total bilirubin < 1.5 mg/dL
• AST and ALT ≤ 2.5 times upper limit of normal
• Serum creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min
• Hemoglobin > 8 g/dL
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception before, during, and for 30 days after completion of study therapy
• Able to take oral medications on a regular basis
• Willing to provide blood samples for mandatory correlative studies
• No condition that impairs the ability to swallow and retain R-(-)-gossypol tablets, including the following:

• Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation
• Active peptic ulcer disease
• No malabsorption syndrome or disease significantly affecting gastrointestinal function
• No ulcerative colitis, inflammatory bowel disease, or a partial or complete small bowel obstruction
• No uncontrolled concurrent illness including, but not limited to, any of the following:

• Ongoing or active infection
• Symptomatic congestive heart failure
• Unstable angina pectoris
• Cardiac arrhythmia
• Psychiatric illness or social situations that would limit compliance with study requirements
• No symptomatic hypercalcemia > grade 2
• No requirement for routine use of hematopoietic growth factors (including G-CSF, GM-CSF, or IL-11) or platelet transfusions to maintain ANC or platelet counts
• No history of allergic reactions attributed to compounds of similar chemical or biologic composition to R-(-)-gossypol
• No HIV positivity
• Recovered from all prior therapy, including prior surgical procedures
• No prior surgical procedures affecting absorption
• No prior resection of the stomach or small bowel
• No more than one prior chemotherapy regimen
• No prior racemic gossypol or R-(-)-gossypol
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)
• At least 4 weeks since prior radiotherapy, hormonal agents, or biologic response modifiers
• At least 4 weeks since prior and no concurrent investigational agents or devices
• No concurrent prophylactic hematopoietic growth factors (including filgrastim [G-CSF], sargramostim [GM-CSF], or interleukin-11 [IL-11]) during course one
• No concurrent combination antiretroviral therapy for HIV-positive patients

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Maria Baggstrom

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Mayo Clinic

Rochester, Minnesota, United States

Countries

United States

Other Identifiers

NCI-2009-01058

Identifier Type: REGISTRY

Identifier Source: secondary_id

MAYO-MC0721

Identifier Type: -

Identifier Source: secondary_id

CDR0000616965

Identifier Type: -

Identifier Source: secondary_id

MC0721

Identifier Type: OTHER

Identifier Source: secondary_id

8027

Identifier Type: OTHER

Identifier Source: secondary_id

N01CM62205

Identifier Type: NIH

Identifier Source: secondary_id

View Link

P30CA015083

Identifier Type: NIH

Identifier Source: secondary_id

View Link

N01CM62209

Identifier Type: NIH

Identifier Source: secondary_id

View Link

NCI-2009-01058

Identifier Type: -

Identifier Source: org_study_id

NCT01647113

Identifier Type: -

Identifier Source: nct_alias